Small-molecule inhibitors or monoclonal antibodies of targeted therapy, such as inhibitors for epidermal growth factor receptor (EGFR) (101), transforming growth factor (TGF)-β (102), BRAF (103), VEGF (104), and MYC (105), can produce impressive tumor responses in selected patients while having potentially fewer side effects. The gene discussed is MYC; the disease is neoplasm.